{"content":"<li class=\"n-box-item date-title\" data-end=\"1513313999\" data-start=\"1513227600\" data-txt=\"Monday, December 23, 2019\">Thursday, December 14, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3318480\" data-ts=\"1513298714\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARRS\" target=\"_blank\">ARRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318480-arris-sinks-after-warning-of-continuing-memory-pricing-pressure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arris sinks after warning of continuing memory pricing pressure</a></h4><ul>   <li>Arris (NASDAQ:<a href='https://seekingalpha.com/symbol/ARRS' title='ARRIS International plc'>ARRS</a>) <font color='red'>fell 6.3%</font> today and touched its lowest point since early September after <a href=\"https://www.sec.gov/Archives/edgar/data/1645494/000114420417063596/tv481371_8k.htm\" target=\"_blank\">holding a call</a> where it said it expects margin pressures from memory pricing to stretch some distance into next year.</li>    <li>Updating on its Ruckus Networks acquisition, the company said it expects to be withing previous revenue guidance for Q4 but \"still has work to do to achieve those results\" (and significant business takes place in the final weeks of the year).</li>    <li>It also said the new Enterprise segment will contribute $40M-$50M in revenues for Q4, neutral to non-GAAP earnings for the period.</li>    <li>Excluding that segment, the Arris business will see modest revenue growth and EPS gains will be highly dependent on memory pricing.</li>    <li>\"Without material improvement in memory costs, profitability in 2018 may be similar to what the company experienced in 2017,\" it notes in an 8-K filing. \"The company continues to work to improve profitability and close the gap to the consensus view for 2018; and similar to 2017, the company currently expects the first quarter of 2018 to be lighter and increase through the year.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318480\" data-linked=\"Arris sinks after warning of continuing memory pricing pressure\" data-tweet=\"$ARRS - Arris sinks after warning of continuing memory pricing pressure https://seekingalpha.com/news/3318480-arris-sinks-after-warning-of-continuing-memory-pricing-pressure?source=tweet\" data-url=\"https://seekingalpha.com/news/3318480-arris-sinks-after-warning-of-continuing-memory-pricing-pressure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318465\" data-ts=\"1513290904\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318465-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='green'>+23.6%</font>. DDR <font color='green'>+10.6%</font>. <a href='https://seekingalpha.com/symbol/HES' title='Hess Corporation'>HES</a> <font color='green'>+6.1%</font>. <a href='https://seekingalpha.com/symbol/QNST' title='QuinStreet, Inc.'>QNST</a> <font color='green'>+5.1%</font>. <a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a> <font color='green'>+5.0%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='red'>-16.4%</font>. <a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a> <font color='red'>-4.4%</font>. <a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a> <font color='red'>-3.8%</font>. <a href='https://seekingalpha.com/symbol/AGTC' title='Applied Genetic Technologies Corporation'>AGTC</a> <font color='red'>-3.3%</font>. <a href='https://seekingalpha.com/symbol/CRTO' title='Criteo S.A.'>CRTO</a> <font color='red'>-2.9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318465\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$DCIX $SITC $HES - After Hours Gainers / Losers https://seekingalpha.com/news/3318465-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3318465-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318452\" data-ts=\"1513288541\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HES\" target=\"_blank\">HES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318452-hessplus-6_8-elliott-presses-for-sale-ceo-removal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hess +6.8% as Elliott presses for sale or CEO removal</a></h4><ul>   <li>Hess (NYSE:<a href='https://seekingalpha.com/symbol/HES' title='Hess Corporation'>HES</a>) is jumping after hours, <font color='green'>up 6.8%</font>, after a <i>Wall Street Journal</i> report that Elliott Management has locked in on the company with an eye to <a href=\"https://www.wsj.com/articles/elliott-management-readies-potential-new-fight-with-hess-corp-1513287440\" target=\"_blank\">removing CEO John Hess</a> unless it can push him to sell it in whole or part.</li>    <li>John Hess, the second-generation CEO, is said by other investors to have a short leash, and activist Elliott holds a 6.7% stake.</li>    <li>Aside from a sale or ousting its CEO, Elliott would like to see capital returned via stock repurchases and is calling for a dividend cut to fund that.</li><li>A previous battle between Elliott and Hess led to John Hess giving up his chairman's role in 2013 and adding Elliott nominees to its board.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318452\" data-linked=\"Hess +6.8% as Elliott presses for sale or CEO removal\" data-tweet=\"$HES - Hess +6.8% as Elliott presses for sale or CEO removal https://seekingalpha.com/news/3318452-hessplus-6_8-elliott-presses-for-sale-ceo-removal?source=tweet\" data-url=\"https://seekingalpha.com/news/3318452-hessplus-6_8-elliott-presses-for-sale-ceo-removal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318451\" data-ts=\"1513288507\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADBE\" target=\"_blank\">ADBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318451-adobe-systemsplus-1_6-on-q4-beats-positive-q1-and-fy18-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adobe Systems +1.6% on Q4 beats, positive Q1 and FY18 guidance</a></h4><ul><li>        Adobe Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a>) shares are&nbsp;<font color='green'>up 1.6%&nbsp;</font>aftermarket following Q4 results that beat EPS and revenue estimates. Q1 guidance has revenue at $2.04B (consensus: $2.04B) and EPS at $1.27 (consensus: $1.24).</li><li>               FY18 guidance raises the revenue estimate from $8.7B to $8.725B (consensus: $8.73B) and reiterates EPS at $5.50 (consensus: $5.52).&nbsp;</li><li>               Revenue: Digital Media revenue was $1.39B with $1.16B from Creative Cloud and the remaining from Document Cloud. Digital Media ARR grew to $5.23B (+$359M Q/Q). Adobe Experience Cloud reported $550M in revenue (+18% Y/Y).&nbsp;</li><li>               Key metrics: Cash flow from operations, $833M; deferred revenue, $2.49B; total operating expenses, $1.1B; cash and equivalents, $2.3B; debt, $1.89B.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17027814-adobe-delivers-record-revenue-2-billion-q4\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318406-adobe-systems-beats-0_10-beats-revenue\" target=\"_blank\">Adobe Systems beats by $0.10, beats on revenue</a> (Dec. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318451\" data-linked=\"Adobe Systems +1.6% on Q4 beats, positive Q1 and FY18 guidance\" data-tweet=\"$ADBE - Adobe Systems +1.6% on Q4 beats, positive Q1 and FY18 guidance https://seekingalpha.com/news/3318451-adobe-systemsplus-1_6-on-q4-beats-positive-q1-and-fy18-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3318451-adobe-systemsplus-1_6-on-q4-beats-positive-q1-and-fy18-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318437\" data-ts=\"1513287416\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBL\" target=\"_blank\">JBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318437-jabilplus-4_6-after-q1-beats-in-line-and-better-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jabil +4.6% after Q1 beats, in-line and better guidance</a></h4><ul><li>        Jabil (NYSE:<a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a>) shares are&nbsp;<font color='green'>up 4.6%&nbsp;</font>aftermarket following a Q1 report that beat EPS and revenue estimates with guidance that&rsquo;s in-line on revenue consensus and beats on EPS. &nbsp;</li><li>        Q2 guidance has revenue from $4.75B to $5.05B (consensus: $4.74B) and EPS from $0.50 to $0.74 (consensus: $0.61). The company expects Diversified Manufacturing Services revenue to increase 25% on the year and Electronics Manufacturing up 1%.</li><li>               Key metrics: Diversified Manufacturing revenue growth, 13%; Electronics Manufacturing growth, 6%; core operating income, $227M; cash and equivalents, $746M.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17027809-jabil-posts-first-quarter-results\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318401-jabil-beats-0_01-beats-revenue\" target=\"_blank\">Jabil beats by $0.01, beats on revenue</a> (Dec. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318437\" data-linked=\"Jabil +4.6% after Q1 beats, in-line and better guidance\" data-tweet=\"$JBL - Jabil +4.6% after Q1 beats, in-line and better guidance https://seekingalpha.com/news/3318437-jabilplus-4_6-after-q1-beats-in-line-and-better-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3318437-jabilplus-4_6-after-q1-beats-in-line-and-better-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318423\" data-ts=\"1513286527\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORCL\" target=\"_blank\">ORCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318423-oracleminus-3_8-aftermarket-despite-q2-cloud-revenue-beats-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oracle -3.8% aftermarket despite Q2, Cloud revenue beats (update)</a></h4><ul><li>Oracle (NYSE:<a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a>) shares are&nbsp;<font color='red'>down 3.8%</font>&nbsp;aftermarket following Q2 results that beat EPS and revenue estimates.</li><li>Revenue: Cloud SaaS revenue, $1.1B (+55% Y/Y); Cloud PaaS plus IaaS, $396M (+21%); total Cloud revenue, $1.5B (+44% compared to the +39% to +43% guidance).</li><li>Key metrics: Operating margin, 44%; short-term deferred revenue, $8.1B (+9%); operating cash flow TTM, $14.6B (+2%); cash and equivalents, $21.3B.</li><li>Share repurchase: Board authorizes increasing the share repurchase program by $12B.</li><li><a href=\"https://seekingalpha.com/pr/17027784-q2-fy18-gaap-eps-8-percent-0_52-non-gaap-eps-14-percent-0_70\" target=\"_blank\">Press release</a></li><li>Conference call is at 5 p.m. Eastern and will stream live at <a href=\"http://www.oracle.com/investor\" target=\"_blank\">this link</a>.</li><li>Will update with guidance after the call.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318399-oracle-beats-0_02-beats-revenue\" target=\"_blank\">Oracle beats by $0.02, beats on revenue</a> (Dec. 14)</li><li>Update with guidance:&nbsp;Oracle Q3 guidance expects Cloud revenue growth from 21% to 25%. Total revenues expected up 2% to 4% or about $9.5B to $9.6B (consensus: $9.68B) with EPS from $0.68 to $0.70 (consensus: $0.72).</li><li>Important guidance note: Oracle said FX tailwinds could drive Q3 revenue growth up to the 5% to 7%. But the company also said FX expectations were lower than predicted.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318423\" data-linked=\"Oracle -3.8% aftermarket despite Q2, Cloud revenue beats (update)\" data-tweet=\"$ORCL - Oracle -3.8% aftermarket despite Q2, Cloud revenue beats (update) https://seekingalpha.com/news/3318423-oracleminus-3_8-aftermarket-despite-q2-cloud-revenue-beats-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3318423-oracleminus-3_8-aftermarket-despite-q2-cloud-revenue-beats-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318416\" data-ts=\"1513286229\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLPG\" target=\"_blank\">GLPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318416-galapagos-elects-to-co-promote-filgotinib-gilead-in-europe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galapagos elects to co-promote filgotinib with Gilead in Europe</a></h4><ul><li>Galapagos NV (NASDAQ:<a href='https://seekingalpha.com/symbol/GLPG' title='Galapagos'>GLPG</a>) <a href=\"https://seekingalpha.com/pr/17027805-galapagos-exercises-co-promotion-option-filgotinib-collaboration-partner-gilead-sciences\" target=\"_blank\">opts in</a> to co-promote JAK1 inhibitor filgotinib with collaboration partner Gilead Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>) in eight European countries.</li><li>It will assume 35% of the co-promotion efforts in Germany, France, Italy, Spain, the UK, the Netherlands, Belgium and Luxembourg. Profits and losses will be equally shared. In Belgium, the Netherlands and Luxembourg, Galapagos will book the sales.</li><li>Outside of the co-promotion territories, Galapagos will be eligible to receive tiered royalties of 20 - 30% on net sales.</li><li>The lockup and standstill arrangement under the companies' January 2016 agreement will expire at month-end.</li><li>Previously: <a href=\"https://seekingalpha.com/news/2989856-galapagos-inks-2_1b-deal-gilead-develop-filgotinib-inflammatory-conditions\" target=\"_blank\">Galapagos inks $2.1B deal with Gilead to develop filgotinib for inflammatory conditions</a> (Dec. 17, 2015)</li><li><strong>Update</strong>: GLPG is up 9% premarket on Friday, December 15.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318416\" data-linked=\"Galapagos elects to co-promote filgotinib with Gilead in Europe\" data-tweet=\"$GLPG $GLPG $GILD - Galapagos elects to co-promote filgotinib with Gilead in Europe https://seekingalpha.com/news/3318416-galapagos-elects-to-co-promote-filgotinib-gilead-in-europe?source=tweet\" data-url=\"https://seekingalpha.com/news/3318416-galapagos-elects-to-co-promote-filgotinib-gilead-in-europe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318406\" data-ts=\"1513285617\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADBE\" target=\"_blank\">ADBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318406-adobe-systems-beats-0_10-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adobe Systems beats by $0.10, beats on revenue</a></h4><ul><li>Adobe Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a>): Q4 EPS of $1.26 <font color='green'>beats by $0.10</font>.</li><li>Revenue of $2B (+24.2% Y/Y) <font color='green'>beats by $50M</font>.</li><li>Shares <font color='green'>+2%</font>.</li><li><a href='https://seekingalpha.com/pr/17027814-adobe-delivers-record-revenue-2-billion-q4'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3318406\" data-linked=\"Adobe Systems beats by $0.10, beats on revenue\" data-tweet=\"$ADBE - Adobe Systems beats by $0.10, beats on revenue https://seekingalpha.com/news/3318406-adobe-systems-beats-0_10-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3318406-adobe-systems-beats-0_10-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318401\" data-ts=\"1513285479\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBL\" target=\"_blank\">JBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318401-jabil-beats-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jabil beats by $0.01, beats on revenue</a></h4><ul><li>Jabil (NYSE:<a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a>): Q1 EPS of $0.80 <font color='green'>beats by $0.01</font>.</li><li>Revenue of $5.59B (+9.6% Y/Y) <font color='green'>beats by $90M</font>.</li><li>Shares <font color='green'>+2%</font>.</li><li><a href='https://seekingalpha.com/pr/17027809-jabil-posts-first-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3318401\" data-linked=\"Jabil beats by $0.01, beats on revenue\" data-tweet=\"$JBL - Jabil beats by $0.01, beats on revenue https://seekingalpha.com/news/3318401-jabil-beats-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3318401-jabil-beats-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318389\" data-ts=\"1513282994\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCSA\" target=\"_blank\">CMCSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318389-report-comcast-higher-offer-fox-preferred-disney-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: Comcast had higher offer, but Fox preferred Disney shares</a></h4><ul>   <li>Comcast (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) is <font color='green'>up 1.5%</font> on a day of heavy catalysts for the country's top cable provider.</li>    <li>Shares moved up to their day's peak after an <a href=\"https://seekingalpha.com/news/3318362-fcc-overturns-net-neutrality-rules-split-vote-updated\" target=\"_blank\">FCC vote to overturn net neutrality regulation</a>, a move widely expected to favor major Internet service providers. They've since trimmed gains a bit.</li>    <li>Meanwhile, they were in the red shortly after the open after confirmation of <a href=\"https://seekingalpha.com/news/3318228-mega-media-disney-confirms-fox-deal\" target=\"_blank\">Disney's deal</a> to buy Fox media assets, a transaction Comcast was heavily invested in <a href=\"https://seekingalpha.com/news/3317606-bloomberg-fox-disney-deal-come-week-stake-murdochs-updated\" target=\"_blank\">until this week</a> when momentum shifted to Disney.</li>    <li>Comcast's offer for the Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a>) assets was actually indicated higher than Disney's (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>), David Faber says, but <a href=\"https://www.cnbc.com/2017/12/14/behind-the-deal-comcast-offer-was-higher-but-fox-preferred-disney-stock.html\" target=\"_blank\">Fox preferred taking Disney's stock</a> to Comcast's.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318389\" data-linked=\"Report: Comcast had higher offer, but Fox preferred Disney shares\" data-tweet=\"$CMCSA $CMCSA $FOX - Report: Comcast had higher offer, but Fox preferred Disney shares https://seekingalpha.com/news/3318389-report-comcast-higher-offer-fox-preferred-disney-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3318389-report-comcast-higher-offer-fox-preferred-disney-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318388\" data-ts=\"1513282088\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XLV\" target=\"_blank\">XLV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318388-healthcare-leads-averages-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare leads averages lower</a></h4><ul><li>The S&amp;P, Dow, and Nasdaq are all&nbsp;<font color='red'>down about 0.25%</font>, but the healthcare sector (<a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a> <font color='red'>-1%</font>) is lit up a brighter share of red.</li><li>Gilead is&nbsp;<font color='red'>down 3.2%</font>, Bristol-Myers&nbsp;<font color='red'>2.55%</font>, Eli Lillly&nbsp;<font color='red'>1.9%</font>, and Merck&nbsp;<font color='red'>1.4%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318388\" data-linked=\"Healthcare leads averages lower\" data-tweet=\"$XLV - Healthcare leads averages lower https://seekingalpha.com/news/3318388-healthcare-leads-averages-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3318388-healthcare-leads-averages-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318383\" data-ts=\"1513281326\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318383-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/OHGI' title='One Horizon Group, Inc.'>OHGI</a> <font color='green'>+191%</font>. <a href='https://seekingalpha.com/symbol/SMIT' title='Schmitt Industries, Inc.'>SMIT</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/VECO' title='Veeco Instruments Inc.'>VECO</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/MITL' title='Mitel Networks Corporation'>MITL</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/APDN' title='Applied DNA Sciences, Inc.'>APDN</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CRTO' title='Criteo S.A.'>CRTO</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/FTR' title='Frontier Communications Corporation'>FTR</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/RBBN' title='Ribbon Communications Inc.'>RBBN</a> <font color='red'>-10%.</font></li> </ul><div class=\"tiny-share-widget\" data-id=\"3318383\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$OHGI $SMIT $VECO - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3318383-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3318383-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318369\" data-ts=\"1513278760\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGEN\" target=\"_blank\">SGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318369-seattle-genetics-continues-slide-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seattle Genetics continues slide, down 7%</a></h4><ul><li>Buyers of Seattle Genetics (<a href='https://seekingalpha.com/symbol/SGEN' title='Seattle Genetics, Inc.'>SGEN</a> <font color='red'>-6.6%</font>) are nowhere to be found, although the selling is on lower-than average volume. Shares have lost&nbsp;<font color='red'>26%</font>&nbsp;of their value since mid-October.</li><li>Investors appear to have lost confidence in the expected upside from Adcetris (brentuximab vedotin) in first-line classical Hodgkin lymphoma &#40;HL&#41;. According to Guggenheim's Adnan Butt, doctors are pushing back on the substantial price differential compared to standard-of-care chemo, $300K versus $4K.</li><li>Data from a Phase 3 study, <a href=\"https://seekingalpha.com/pr/17022732-takeda-seattle-genetics-present-positive-data-phase-3-echelonminus-1-clinical-trial\" target=\"_blank\">ECHELON-1</a>, showed that HL patients treated with the combination of Adcetris + AVD chemo in a first-line setting experienced an 86% response rate, only slightly better than 83% for the chemo regimen alone.</li><li>Despite the uninspiring situation, Mr. Butt remains bullish on the stock and sees peak Adcetris sales of $1B for the indication, noting that while doctors may be on the fence, patients shouldn't be if they don't have significant out-of-pocket costs.</li><li>Source for analyst comments: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3307478-seattle-genetics-files-u-s-marketing-application-expanded-use-adcetris\" target=\"_blank\">Seattle Genetics files U.S. marketing application for expanded use of Adcetris</a> (Nov. 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318369\" data-linked=\"Seattle Genetics continues slide, down 7%\" data-tweet=\"$SGEN - Seattle Genetics continues slide, down 7% https://seekingalpha.com/news/3318369-seattle-genetics-continues-slide-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3318369-seattle-genetics-continues-slide-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318374\" data-ts=\"1513278209\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRCO\" target=\"_blank\">TRCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318374-fcc-votes-to-review-national-tv-ownership-cap-updated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FCC votes to review national TV ownership cap (updated)</a></h4><ul>   <li>As its final agenda item on a day where it <a href=\"https://seekingalpha.com/news/3318362-fcc-overturns-net-neutrality-rules-split-vote\" target=\"_blank\">repealed its net neutrality regulations</a>, the FCC also voted on another split 3-2 vote to review the national TV audience reach cap that limits ownership of local broadcast stations by a single entity.</li>    <li>Those rules cap an aggregate reach at 39% of U.S. TV households.</li>    <li>The move's a bit controversial as the cap was set by Congress rather than the commission, and there's debate even inside the agency about its authority to review the limit.</li>    <li>The rule change was seen (<a href=\"https://seekingalpha.com/news/3313094-local-media-shares-gain-fcc-ownership-rule-rollback\" target=\"_blank\">along with earlier moves</a> that also reinstated the \"UHF discount\") as a key component in a buyout of Tribune Media (NYSE:<a href='https://seekingalpha.com/symbol/TRCO' title='Tribune Media Company'>TRCO</a>) by Sinclair Broadcast Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SBGI' title='Sinclair Broadcast Group, Inc.'>SBGI</a>) to create a local broadcasting giant.</li>    <li>That combination would hold 233 stations and reach 72% of the country. <a href='https://seekingalpha.com/symbol/SBGI' title='Sinclair Broadcast Group, Inc.'>SBGI</a>, <font color='green'>up as much as 2.1%</font> earlier, has dropped into the red, <font color='red'>-0.2%</font>; <a href='https://seekingalpha.com/symbol/TRCO' title='Tribune Media Company'>TRCO</a> has trimmed <font color='green'>gains to 0.5%</font>.</li>    <li>Other local-media players: <a href='https://seekingalpha.com/symbol/TGNA' title='TEGNA'>TGNA</a>; TRNC; <a href='https://seekingalpha.com/symbol/NEWM' title='New Media'>NEWM</a>; <a href='https://seekingalpha.com/symbol/GCI' title='Gannett Co., Inc.'>GCI</a>; <a href='https://seekingalpha.com/symbol/MNI' title='The McClatchy Company'>MNI</a>; <a href='https://seekingalpha.com/symbol/GTN' title='Gray Television, Inc.'>GTN</a>; <a href='https://seekingalpha.com/symbol/SSP' title='The E.W. Scripps Company'>SSP</a>; <a href='https://seekingalpha.com/symbol/NXST' title='Nexstar Media Group, Inc.'>NXST</a>.</li><li><strong>Updated 2:15 p.m.:</strong> Related to the FCC's earlier action, New York Attorney General Eric Schneiderman says he will <a href=\"https://www.cnbc.com/2017/12/14/new-york-attorney-general-schneiderman-will-sue-over-net-neutrality.html?__source=twitter|main\" target=\"_blank\">lead a multi-state lawsuit</a> to stop an \"illegal rollback of net neutrality.\" The move is an \"early Christmas present\" for Big Telecom, he says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318374\" data-linked=\"FCC votes to review national TV ownership cap (updated)\" data-tweet=\"$TRCO $TRCO $SBGI - FCC votes to review national TV ownership cap (updated) https://seekingalpha.com/news/3318374-fcc-votes-to-review-national-tv-ownership-cap-updated?source=tweet\" data-url=\"https://seekingalpha.com/news/3318374-fcc-votes-to-review-national-tv-ownership-cap-updated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318371\" data-ts=\"1513278052\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318371-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd'>NAK</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ROSE' title='Rosehill Resources Inc.'>ROSE</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/GPP' title='Green Plains Partners'>GPP</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SE' title='Sea Ltd'>SE</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318371\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$OSN $NAK $YTEN - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3318371-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3318371-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318367\" data-ts=\"1513276947\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIEB\" target=\"_blank\">SIEB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318367-siebert-financial-up-60-on-crypto-trading-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Siebert Financial up 60% on crypto trading deal</a></h4><ul><li>The company today announced a deal to offer $2.99 stock trades through Overstock.com.</li><li>What's really probably moving the stock is the partnership with Overstock's tZERO subsidiary: That means blockchain and trading in cryptocurrencies.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17027337-b-siebert-b-financial-corp-overstock-tzero-execute-letter-intent-offer-discount-trading\" target=\"_blank\">Press Release</a></li><li><a href='https://seekingalpha.com/symbol/SIEB' title='Siebert Financial Corp.'>SIEB</a>&nbsp;<font color='green'>+60.75%</font></li><li>Previously: <a href=\"https://seekingalpha.com/news/3318361-overstock-offer-discount-online-trading-via-tzero-siebert-deal\" target=\"_blank\">Overstock to offer discount online trading via tZERO-Siebert deal</a> (Dec. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318367\" data-linked=\"Siebert Financial up 60% on crypto trading deal\" data-tweet=\"$SIEB - Siebert Financial up 60% on crypto trading deal https://seekingalpha.com/news/3318367-siebert-financial-up-60-on-crypto-trading-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3318367-siebert-financial-up-60-on-crypto-trading-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318363\" data-ts=\"1513275657\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318363-moodys-to-review-tevas-rating-for-possible-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moody&#39;s to review Teva&#39;s rating for possible downgrade</a></h4><ul><li>Showering a bit of rain on Teva's (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='green'>+10.4%</font>) restructuring announcement parade, Moody's <a href=\"https://www.moodys.com/research/Moodys-places-Tevas-Baa3-ratings-on-review-for-downgrade--PR_377180\" target=\"_blank\">reports </a>that it has placed the company's senior unsecured rating of Baa3 under review for a possible downgrade.</li><li>While acknowledging the positive aspects of its restructuring and cost-cutting plans, Moody's says management's statement that it will not pursue an equity raise adds to operational risk considering medium-term weakness in generics and pricing pressure on top seller Copaxone.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318233-teva-cut-workforce-25-percent-suspends-dividend-shares-3-percent-premarket\" target=\"_blank\">Teva to cut workforce 25%, suspends dividend; shares up 3% premarket</a> (Dec. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318363\" data-linked=\"Moody&#39;s to review Teva&#39;s rating for possible downgrade\" data-tweet=\"$TEVA - Moody&#39;s to review Teva&#39;s rating for possible downgrade https://seekingalpha.com/news/3318363-moodys-to-review-tevas-rating-for-possible-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3318363-moodys-to-review-tevas-rating-for-possible-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318360\" data-ts=\"1513275088\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JNPR\" target=\"_blank\">JNPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318360-juniper-networks-ceo-doesnt-confirm-deny-acquisition-potential\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Juniper Networks CEO doesn&#39;t confirm or deny acquisition potential</a></h4><ul><li>        Juniper Networks (NYSE:<a href='https://seekingalpha.com/symbol/JNPR' title='Juniper Networks'>JNPR</a>) CEO Rami Rahim responds to <a href=\"https://www.marketwatch.com/story/juniper-ceo-still-seeking-clouds-silver-lining-amid-acquisition-rumors-2017-12-13\" target=\"_blank\">MarketWatch&rsquo;s</a> question about whether the company is a likely acquisition target: &ldquo;I am running this company for stand-alone success.&rdquo;</li><li>               Rahim became the CEO about three years ago and has led the company&rsquo;s shift toward data centers and cloud services. The shift comes with some struggles including a weak Q4 outlook and unstable gross margins.&nbsp;</li><li>               Juniper Networks shares are&nbsp;<font color='red'>down 0.48%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316310-juniper-networks-announces-telecom-partnership-self-driving-network\" target=\"_blank\">Juniper Networks announces telecom partnership for a self-driving network</a> (Dec. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318360\" data-linked=\"Juniper Networks CEO doesn&#39;t confirm or deny acquisition potential\" data-tweet=\"$JNPR - Juniper Networks CEO doesn&#39;t confirm or deny acquisition potential https://seekingalpha.com/news/3318360-juniper-networks-ceo-doesnt-confirm-deny-acquisition-potential?source=tweet\" data-url=\"https://seekingalpha.com/news/3318360-juniper-networks-ceo-doesnt-confirm-deny-acquisition-potential\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318359\" data-ts=\"1513274820\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRGO\" target=\"_blank\">PRGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318359-perrigo-to-bid-for-german-mercks-consumer-health-unit-reuters\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Perrigo to bid for German Merck&#39;s consumer health unit - Reuters</a></h4><ul><li>Reuters <a href=\"https://af.reuters.com/article/commodities07News/idAFL8N1OE6SN\" target=\"_blank\">reports </a>that Perrigo (<a href='https://seekingalpha.com/symbol/PRGO' title='Perrigo Company'>PRGO</a> <font color='red'>-1.8%</font>) is preparing an offer for Merck KGaA's (<a href='https://seekingalpha.com/symbol/MKGAF' title='Merck KGaA'>OTCPK:MKGAF</a>)(<a href='https://seekingalpha.com/symbol/MKGAY' title='Merck KGaA ADR'>OTCPK:MKGAY</a>) consumer health business, expected to fetch ~US$4.8B.</li><li>Perrigo will be competing against Nestle and privately owned Strada for the business.</li><li>Merck advisor JPMorgan wants a short list of suitors by month-end.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3315826-suitors-preparing-bids-merck-kgaas-consumer-health-unit\" target=\"_blank\">Suitors preparing bids for Merck KgaA's consumer health unit</a> (Dec. 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318359\" data-linked=\"Perrigo to bid for German Merck&#39;s consumer health unit - Reuters\" data-tweet=\"$PRGO $PRGO $MKGAF - Perrigo to bid for German Merck&#39;s consumer health unit - Reuters https://seekingalpha.com/news/3318359-perrigo-to-bid-for-german-mercks-consumer-health-unit-reuters?source=tweet\" data-url=\"https://seekingalpha.com/news/3318359-perrigo-to-bid-for-german-mercks-consumer-health-unit-reuters\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318354\" data-ts=\"1513274003\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FXC\" target=\"_blank\">FXC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318354-loonie-strengthens-poloz-grows-increasingly-confident\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Loonie strengthens as Poloz grows &#39;increasingly confident&#39;</a></h4><ul><li>Bank of Canada Governor Stephen Poloz&nbsp;<a href=\"https://www.bankofcanada.ca/multimedia/canadian-club-toronto-speech-webcasts-14-december-2017/\" target=\"_blank\">says the economy</a> has made \"tremendous progress\" over the past year, and the bank is \"increasingly confident\" it can continue to tighten monetary policy.</li><li>The bank, nevertheless, will remain cautious with rate hikes.</li><li>Down vs. the dollar earlier, the loonie (NYSEARCA:<a href='https://seekingalpha.com/symbol/FXC' title='Invesco CurrencyShares Canadian Dollar Trust ETF'>FXC</a>) is now&nbsp;<font color='green'>higher by 0.25%</font>&nbsp;at $0.7822.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318354\" data-linked=\"Loonie strengthens as Poloz grows &#39;increasingly confident&#39;\" data-tweet=\"$FXC - Loonie strengthens as Poloz grows &#39;increasingly confident&#39; https://seekingalpha.com/news/3318354-loonie-strengthens-poloz-grows-increasingly-confident?source=tweet\" data-url=\"https://seekingalpha.com/news/3318354-loonie-strengthens-poloz-grows-increasingly-confident\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318348\" data-ts=\"1513273997\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NXTM\" target=\"_blank\">NXTM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318348-nxstage-medical-under-modest-pressure-on-slow-pace-of-acquirer-fresenius-to-work-through-u-s\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NxStage Medical under modest pressure on slow pace of acquirer Fresenius to work through U.S. antitrust issues; shares down a fraction</a></h4><ul><li>NxStage Medical (<a href='https://seekingalpha.com/symbol/NXTM' title='NxStage Medical, Inc.'>NXTM</a> <font color='red'>-0.5%</font>) eases on light volume in apparent response to a report on CTFN saying U.S. regulatory review of its announced $2B merger with Fresenius Medical Care (<a href='https://seekingalpha.com/symbol/FMS' title='Fresenius Medical Care AG & Co. KGAA'>FMS</a> <font color='red'>-1.1%</font>) is proceeding slowly.</li><li>According to a source close to the matter, Fresenius has yet to certify substantial compliance with the U.S. Federal Trade Commission's second request and has yet to enter a timing agreement with the regulator.</li><li>The methodical FTC review is not unexpected. The companies set the transaction drop dead date out 18 months in anticipation of a thorough assessment of the merits of the merger.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3286103-fmc-buy-nxstage-2b\" target=\"_blank\">FMC to buy NxStage for $2B</a> (Aug. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318348\" data-linked=\"NxStage Medical under modest pressure on slow pace of acquirer Fresenius to work through U.S. antitrust issues; shares down a fraction\" data-tweet=\"$NXTM $NXTM $FMS - NxStage Medical under modest pressure on slow pace of acquirer Fresenius to work through U.S. antitrust issues; shares down a fraction https://seekingalpha.com/news/3318348-nxstage-medical-under-modest-pressure-on-slow-pace-of-acquirer-fresenius-to-work-through-u-s?source=tweet\" data-url=\"https://seekingalpha.com/news/3318348-nxstage-medical-under-modest-pressure-on-slow-pace-of-acquirer-fresenius-to-work-through-u-s\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318353\" data-ts=\"1513273535\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318353-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/OHGI' title='One Horizon Group, Inc.'>OHGI</a> <font color='green'>+82%</font>. <a href='https://seekingalpha.com/symbol/SIEB' title='Siebert Financial Corp.'>SIEB</a> <font color='green'>+62%</font>. <a href='https://seekingalpha.com/symbol/SMIT' title='Schmitt Industries, Inc.'>SMIT</a> <font color='green'>+44%</font>. <a href='https://seekingalpha.com/symbol/AMPE' title='Ampio Pharmaceuticals, Inc.'>AMPE</a> <font color='green'>+37%</font>. <a href='https://seekingalpha.com/symbol/GHDX' title='Genomic Health, Inc.'>GHDX</a> <font color='green'>+20%</font>. CLNT <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/NDSN' title='Nordson Corporation'>NDSN</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/ARQL' title='ArQule, Inc.'>ARQL</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/HMG' title='HMG/Courtland Properties, Inc'>HMG</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PIR' title='Pier 1 Imports Inc.'>PIR</a> <font color='red'>-30%</font>. <a href='https://seekingalpha.com/symbol/CRTO' title='Criteo S.A.'>CRTO</a> <font color='red'>-27%</font>. COOL <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/FTR' title='Frontier Communications Corporation'>FTR</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/ABM' title='ABM Industries Incorporated'>ABM</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/TNTR-OLD' title='Tintri, Inc.'>TNTR-OLD</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/VERU' title='Veru Inc.'>VERU</a> <font color='red'>-12%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318353\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$OHGI $SIEB $SMIT - Midday Gainers / Losers https://seekingalpha.com/news/3318353-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3318353-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318345\" data-ts=\"1513270910\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318345-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> LTEA <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/FUV' title='Arcimoto, Inc.'>FUV</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/KODK' title='Eastman Kodak Co.'>KODK</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corp'>VUZI</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/SAFM' title='Sanderson Farms, Inc.'>SAFM</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/ZX' title='China Zenix Auto International'>ZX</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318345\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$LBCC $FUV $KODK - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3318345-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3318345-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318343\" data-ts=\"1513270419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USB\" target=\"_blank\">USB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318343-banks-ease-bit-following-rate-hike\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Banks ease a bit following rate hike</a></h4><ul><li>There's been a flurry of prime rate increases announced following the FOMC's latest 25 basis point hike in the Fed Funds rate. We're looking hard, <a href=\"https://www.marketwatch.com/story/banks-are-still-not-passing-on-higher-fed-rates-to-savers-2017-12-14\" target=\"_blank\">but haven't been able to find</a> one notice of a boost in deposit rates.</li><li>Markets anticipate though, so despite this largess visited upon the nation's lenders, their stock prices are slipping just a bit.</li><li>The SPDR KBW Bank ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/KBE' title='SPDR S&P Bank ETF'>KBE</a>) is<font color='red'> lower by 0.15%</font>&nbsp;today, and now&nbsp;<font color='red'>down about 2%</font>&nbsp;since yesterday afternoon. The Regional Bank ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a>) is seeing similar action.</li><li>Individual issues: U.S. Bancorp (<a href='https://seekingalpha.com/symbol/USB' title='U.S. Bancorp'>USB</a> <font color='red'>-0.2%</font>), Regions Financial (<a href='https://seekingalpha.com/symbol/RF' title='Regions Financial Corporation'>RF</a> <font color='red'>-0.3%</font>), New York Community (<a href='https://seekingalpha.com/symbol/NYCB' title='New York Community Bancorp Inc.'>NYCB</a>), Huntington (<a href='https://seekingalpha.com/symbol/HBAN' title='Huntington Bancshares Incorporated'>HBAN</a> <font color='red'>-0.7%</font>), PNC Financial (<a href='https://seekingalpha.com/symbol/PNC' title='PNC Financial Services Group, Inc.'>PNC</a>), BB&amp; T(<a href='https://seekingalpha.com/symbol/BBT' title='BB&T Corporation'>BBT</a> <font color='red'>-0.1%</font>), Fifth Third (<a href='https://seekingalpha.com/symbol/FITB' title='Fifth Third Bancorp'>FITB</a> <font color='red'>-0.5%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318343\" data-linked=\"Banks ease a bit following rate hike\" data-tweet=\"$USB $KBE $KRE - Banks ease a bit following rate hike https://seekingalpha.com/news/3318343-banks-ease-bit-following-rate-hike?source=tweet\" data-url=\"https://seekingalpha.com/news/3318343-banks-ease-bit-following-rate-hike\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318340\" data-ts=\"1513269690\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBOT\" target=\"_blank\">MBOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318340-microbot-nabs-new-u-s-patent-covering-tipcat-platform-shares-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microbot nabs new U.S. patent covering TipCAT platform; shares up 6%</a></h4><ul><li>The USPTO <a href=\"https://seekingalpha.com/pr/17026875-microbot-receives-notice-allowance-u-s-patent-covering-tipcat-technology-platform\" target=\"_blank\">issues </a>a Notice of Allowance to Microbot Medical (<a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc'>MBOT</a> <font color='green'>+6%</font>) in response to its Application No. 14/746,660, a continuation of U.S. Patent No. 9,061,118 covering its <a href=\"http://www.microbotmedical.com/technology/tipcat/\" target=\"_blank\">TipCAT </a>device, a self-propelled semi-disposable endoscope.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318340\" data-linked=\"Microbot nabs new U.S. patent covering TipCAT platform; shares up 6%\" data-tweet=\"$MBOT - Microbot nabs new U.S. patent covering TipCAT platform; shares up 6% https://seekingalpha.com/news/3318340-microbot-nabs-new-u-s-patent-covering-tipcat-platform-shares-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3318340-microbot-nabs-new-u-s-patent-covering-tipcat-platform-shares-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318335\" data-ts=\"1513268337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ELY\" target=\"_blank\">ELY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318335-callaway-golf-rallies-after-jpmorgan-raves\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Callaway Golf rallies after JPMorgan raves</a></h4><ul> <li>Callaway Golf (<a href='https://seekingalpha.com/symbol/ELY' title='Callaway Golf Company'>ELY</a> <font color='green'>+5.2%</font>) jumps after JPMorgan starts off coverage with a strong endorsement of the company's upside potential to back up its Overweight rating.</li> <li>Callaway's \"innovative\" product portfolio is singled out amid a golf industry seen as stabilizing.</li> <li>During <a href=\"https://seekingalpha.com/news/3304628-blowout-numbers-callaway-golf\" target=\"_blank\">Q3</a>, Callaway posted golf club sales growth of 20% and gold ball sales growth of 21% on strength across geographic regions.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318335\" data-linked=\"Callaway Golf rallies after JPMorgan raves\" data-tweet=\"$ELY - Callaway Golf rallies after JPMorgan raves https://seekingalpha.com/news/3318335-callaway-golf-rallies-after-jpmorgan-raves?source=tweet\" data-url=\"https://seekingalpha.com/news/3318335-callaway-golf-rallies-after-jpmorgan-raves\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318334\" data-ts=\"1513267985\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GHDX\" target=\"_blank\">GHDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318334-genomic-health-drawing-takeover-interest-shares-ahead-20\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genomic Health drawing takeover interest; shares ahead 20%</a></h4><ul><li>Thinly traded Genomic Health (<a href='https://seekingalpha.com/symbol/GHDX' title='Genomic Health, Inc.'>GHDX</a> <font color='green'>+19.5%</font>) is up on almost a 4x surge in volume, albeit on turnover of only 452K shares, in response to a Bloomberg <a href=\"https://www.streetinsider.com/Hot+M+and+A/Genomic+Health+%28GHDX%29+Said+to+Explore+Options+Including+Sale+Amid+Takeover+Interest+-+Bloomberg/13601128.html\" target=\"_blank\">report </a>that it is exploring strategic options, including a sale of the company, after receiving takeover interest.</li><li>The company provides oncology diagnostic services. Its lead test is <a href=\"http://www.genomichealth.com/en-US/oncotype_iq_products/oncotype_dx\" target=\"_blank\">Oncotype DX</a> for breast, colon and prostate cancer.</li><li>Competitor Myriad Genetics (<a href='https://seekingalpha.com/symbol/MYGN' title='Myriad Genetics, Inc.'>MYGN</a> <font color='red'>-0.8%</font>) is down on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318334\" data-linked=\"Genomic Health drawing takeover interest; shares ahead 20%\" data-tweet=\"$GHDX $GHDX $MYGN - Genomic Health drawing takeover interest; shares ahead 20% https://seekingalpha.com/news/3318334-genomic-health-drawing-takeover-interest-shares-ahead-20?source=tweet\" data-url=\"https://seekingalpha.com/news/3318334-genomic-health-drawing-takeover-interest-shares-ahead-20\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318311\" data-ts=\"1513267256\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318311-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AMPE' title='Ampio Pharmaceuticals, Inc.'>AMPE</a> <font color='green'>+49%</font>. <a href='https://seekingalpha.com/symbol/GHDX' title='Genomic Health, Inc.'>GHDX</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/ARQL' title='ArQule, Inc.'>ARQL</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/EYES' title='Second Sight Medical Products'>EYES</a> <font color='red'>-13%</font>. COOL <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/VERU' title='Veru Inc.'>VERU</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/CYTR' title='CytRx Corporation'>CYTR</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318311\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$AMPE $GHDX $TEVA - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3318311-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3318311-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318330\" data-ts=\"1513266977\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TROV\" target=\"_blank\">TROV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318330-trovagene-readies-mid-stage-study-of-pcmminus-075-zytiga-combo-in-prostate-cancer-shares-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TrovaGene readies mid-stage study of PCM-075/Zytiga combo in prostate cancer; shares down 4% as downtrend continues</a></h4><ul><li>TrovaGene (<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a> <font color='red'>-4.3%</font>) has filed with the FDA its <a href=\"https://seekingalpha.com/pr/17027005-trovagene-submits-protocol-fda-phase-2-clinical-trial-pcmminus-075-combination-zytiga\" target=\"_blank\">proposed protocol</a> for a Phase 2 study assessing the combination of PCM-075, Johnson &amp; Johnson's <a href=\"https://www.zytiga.com/\" target=\"_blank\">Zytiga </a>(abiraterone acetate) and prednisone in patients with metastatic castration-resistant prostate cancer.</li><li>The primary endpoint of the 25-subject trial will be the proportion of subjects achieving disease control at week 12 as defined by the lack of progression of the prostate cancer biomarker PSA (prostate-specific antigen).</li><li>PCM-075 inhibits an enzyme called serine/threonine polo-like-kinase 1 (PLK 1) which is overexpressed in a range of blood cancers and solid tumors. Studies have shown that inhibiting polo-like-kinases can lead to cancer cell death.</li><li>Shares continue their downward march. One factor is the company's planned <a href=\"https://www.sec.gov/Archives/edgar/data/1213037/000119312517367579/d469137ds1a.htm\" target=\"_blank\">equity offering</a> of up to ~16M Units (stock + warrant).</li></ul><div class=\"tiny-share-widget\" data-id=\"3318330\" data-linked=\"TrovaGene readies mid-stage study of PCM-075/Zytiga combo in prostate cancer; shares down 4% as downtrend continues\" data-tweet=\"$TROV - TrovaGene readies mid-stage study of PCM-075/Zytiga combo in prostate cancer; shares down 4% as downtrend continues https://seekingalpha.com/news/3318330-trovagene-readies-mid-stage-study-of-pcmminus-075-zytiga-combo-in-prostate-cancer-shares-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3318330-trovagene-readies-mid-stage-study-of-pcmminus-075-zytiga-combo-in-prostate-cancer-shares-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318329\" data-ts=\"1513266708\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KR\" target=\"_blank\">KR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318329-kroger-best-idea-hedgeye\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kroger a &#39;Best Idea&#39; at Hedgeye</a></h4><ul> <li>Kroger (<a href='https://seekingalpha.com/symbol/KR' title='Kroger Co.'>KR</a> <font color='red'>-0.2%</font>) lands on the Best Ideas list at Hedgeye.</li> <li>Analyst Howard Penney points to the easy stretch of comparisons for the grocery store chain in 2018 and thinks the aggressive positioning by the company will pay off.</li> <li>Shares of Kroger are down 23% YTD, with a bulk of that drop a one-day shock to the system from Amazon's purchase of Whole Foods.</li><li>Sources: Bloomberg, Morningstar</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318329\" data-linked=\"Kroger a &#39;Best Idea&#39; at Hedgeye\" data-tweet=\"$KR - Kroger a &#39;Best Idea&#39; at Hedgeye https://seekingalpha.com/news/3318329-kroger-best-idea-hedgeye?source=tweet\" data-url=\"https://seekingalpha.com/news/3318329-kroger-best-idea-hedgeye\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318328\" data-ts=\"1513266499\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MARK\" target=\"_blank\">MARK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318328-remark-selected-ai-provider-for-worlds-largest-coal-mining-company\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Remark selected as AI provider for world&#39;s largest coal mining company</a></h4><ul><li>        Remark Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a>) <a href=\"http://ir.remarkholdings.com/releasedetail.cfm?ReleaseID=1051756\" target=\"_blank\">announces</a> that China Shenhua Energy Company has selected Remark&rsquo;s KanKan as its AI tech partner.</li><li>               Shenhua will use KanKan&rsquo;s facial and gesture recognition and tracking capabilities to improve worker management and mining and construction safety.&nbsp;&nbsp;</li><li>        China Shenhua is state-owned and the largest coal mining business in the world. &nbsp;</li><li>        Remark shares are&nbsp;<font color='red'>down 0.12%</font>.&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3318328\" data-linked=\"Remark selected as AI provider for world&#39;s largest coal mining company\" data-tweet=\"$MARK - Remark selected as AI provider for world&#39;s largest coal mining company https://seekingalpha.com/news/3318328-remark-selected-ai-provider-for-worlds-largest-coal-mining-company?source=tweet\" data-url=\"https://seekingalpha.com/news/3318328-remark-selected-ai-provider-for-worlds-largest-coal-mining-company\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318326\" data-ts=\"1513266171\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WNC\" target=\"_blank\">WNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318326-wabash-national-slumps-after-otr-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wabash National slumps after OTR downgrade</a></h4><ul> <li>Wabash National (<a href='https://seekingalpha.com/symbol/WNC' title='Wabash National Corporation'>WNC</a> <font color='red'>-4%</font>) slides after OTR Global issues a downgrade on the commercial truck manufacturer to Mixed from Positive. Concerns over the company's positioning with fleets are cited. Earlier this year, Wabash swallowed up Supreme Industries to add new products to the mix.</li> <li>Shares of Wabash fell below $20 after the ratings slap. The 52-week trading range on WNC is $14.97 to $24.15.</li> <li>Sources: CNBC, Fleet Equipment Magazine</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318326\" data-linked=\"Wabash National slumps after OTR downgrade\" data-tweet=\"$WNC - Wabash National slumps after OTR downgrade https://seekingalpha.com/news/3318326-wabash-national-slumps-after-otr-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3318326-wabash-national-slumps-after-otr-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318321\" data-ts=\"1513265409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318321-eia-natural-gas-inventory\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EIA Natural Gas Inventory</a></h4><ul>     <li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory</a>: <strong>-69 Bcf</strong> vs. -60 Bcf consensus, +2 Bcf last week.</li>     <li>Futures&nbsp;<font color='red'>-0.99%</font>&nbsp;to $2.688.</li>     <li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>,<a href='https://seekingalpha.com/symbol/DCNG' title='iPath Pure Beta Seasonal Natural Gas ETN'>DCNG</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318321\" data-linked=\"EIA Natural Gas Inventory\" data-tweet=\"$UNG $DGAZ $UGAZ - EIA Natural Gas Inventory https://seekingalpha.com/news/3318321-eia-natural-gas-inventory?source=tweet\" data-url=\"https://seekingalpha.com/news/3318321-eia-natural-gas-inventory\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>118&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318320\" data-ts=\"1513265383\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNDM\" target=\"_blank\">TNDM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318320-tandem-diabetes-nabs-new-u-s-patent-covering-insulin-delivery-technology-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tandem Diabetes nabs new U.S. patent covering insulin delivery technology; shares up 3%</a></h4><ul><li>The USPTO <a href=\"https://seekingalpha.com/pr/17027209-tandem-diabetes-care-announces-issuance-patent-related-automated-insulin-delivery-technology\" target=\"_blank\">issues </a>U.S. Patent No. 9,833,177 to Tandem Diabetes Care (<a href='https://seekingalpha.com/symbol/TNDM' title='Tandem Diabetes Care, Inc.'>TNDM</a> <font color='green'>+2.8%</font>) covering the pump system that suspends the delivery of insulin to a user if the device senses glucose below a certain level, alerts the user and recommends he/she initiate a blood glucose measurement. The patent will be valid until December 2028.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318320\" data-linked=\"Tandem Diabetes nabs new U.S. patent covering insulin delivery technology; shares up 3%\" data-tweet=\"$TNDM - Tandem Diabetes nabs new U.S. patent covering insulin delivery technology; shares up 3% https://seekingalpha.com/news/3318320-tandem-diabetes-nabs-new-u-s-patent-covering-insulin-delivery-technology-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3318320-tandem-diabetes-nabs-new-u-s-patent-covering-insulin-delivery-technology-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318317\" data-ts=\"1513264390\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APRN\" target=\"_blank\">APRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318317-blue-apron-rallies-after-insider-buying-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blue Apron rallies after insider buying action</a></h4><ul>     <li>Shares of Blue Apron (NYSE:<a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a>) perk up in early trading after the company discloses that CEO Brad Dickerson gobbled up 180K shares this week in a price range of $3.87 to $3.95.</li>  <li><a href=\"https://www.sec.gov/Archives/edgar/data/1428648/000110465917073194/xslF345X03/a4.xml\" target=\"_blank\">SEC Form 4</a></li>     <li>APRN <font color='green'>+4.53%</font> premarket to $4.15.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3318317\" data-linked=\"Blue Apron rallies after insider buying action\" data-tweet=\"$APRN - Blue Apron rallies after insider buying action https://seekingalpha.com/news/3318317-blue-apron-rallies-after-insider-buying-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3318317-blue-apron-rallies-after-insider-buying-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318309\" data-ts=\"1513263077\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318309-akcea-launches-mid-stage-study-of-lica-candidate-in-patients-diabetes-high-triglycerides-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akcea launches mid-stage study of LICA candidate in patients with diabetes, high triglycerides and fatty liver disease; shares up 3%</a></h4><ul><li>Ionis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a> <font color='red'>-1.4%</font>) affiliate Akcea Therapeutics (<a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics'>AKCA</a> <font color='green'>+2.6%</font>) <a href=\"https://seekingalpha.com/pr/17026867-akcea-initiates-phase-2-study-akcea-angptl3-lrx-patients-hypertriglyceridemia-type-2-diabetes\" target=\"_blank\">launches </a>a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03371355?intr=akcea-angptl3-lrx&amp;rank=2\" target=\"_blank\">Phase 2 clinical trial</a> assessing AKCEA-ANGPTL3-Lrx in patients with diabetes, hypertriglyceridemia (high blood triglycerides) and nonalcoholic fatty liver disease &#40;NAFLD&#41;.</li><li>The primary objectives are to determine the optimal dose and dosing regimen for future pivotal studies. Topline data from the 114-subject study should be available in 2019.</li><li>AKCEA-ANGPTL3-Lrx, a ligand-conjugated antisense &#40;LICA&#41; drug, is designed to target and reduce the production a liver protein called angiopoietin-like 3 (ANGPTL3). People with an inherited absence of ANGPTL3 have lower lipid levels and reduced risk of insulin resistance, diabetes and cardiovascular disease compared to people with normal levels of the protein.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318309\" data-linked=\"Akcea launches mid-stage study of LICA candidate in patients with diabetes, high triglycerides and fatty liver disease; shares up 3%\" data-tweet=\"$IONS $IONS $AKCA - Akcea launches mid-stage study of LICA candidate in patients with diabetes, high triglycerides and fatty liver disease; shares up 3% https://seekingalpha.com/news/3318309-akcea-launches-mid-stage-study-of-lica-candidate-in-patients-diabetes-high-triglycerides-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3318309-akcea-launches-mid-stage-study-of-lica-candidate-in-patients-diabetes-high-triglycerides-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318303\" data-ts=\"1513262138\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRNA\" target=\"_blank\">DRNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318303-dicerna-prices-stock-offering-7-shares-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dicerna prices stock offering at $7; shares down 7%</a></h4><ul><li>Dicerna Pharmaceuticals (<a href='https://seekingalpha.com/symbol/DRNA' title='Dicerna Pharmaceuticals, Inc.'>DRNA</a> <font color='red'>-6.8%</font>) <a href=\"https://seekingalpha.com/pr/17027338-dicerna-announces-pricing-follow-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of ~5.7M shares of common stock at $7.00 per share. Underwriters over-allotment is an additional ~857K shares. Closing date is December 18.</li><li>Net proceeds will fund preclinical and clinical development, platform development, working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318303\" data-linked=\"Dicerna prices stock offering at $7; shares down 7%\" data-tweet=\"$DRNA - Dicerna prices stock offering at $7; shares down 7% https://seekingalpha.com/news/3318303-dicerna-prices-stock-offering-7-shares-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3318303-dicerna-prices-stock-offering-7-shares-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318300\" data-ts=\"1513261731\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GTN\" target=\"_blank\">GTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318300-gray-televisionplus-1_7-on-jefferies-launch-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gray Television +1.7% on Jefferies launch at Buy</a></h4><ul>   <li>Gray Television (NYSE:<a href='https://seekingalpha.com/symbol/GTN' title='Gray Television, Inc.'>GTN</a>) is <font color='green'>up 1.7%</font> premarket after getting an initiation at Buy by Jefferies.</li>    <li>The firm settles in alongside other Street price targets (part of six other Buy ratings) at $18, implying 22% upside.</li>    <li>Shares have <font color='green'>gained 39.5%</font> over the past 12 months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318300\" data-linked=\"Gray Television +1.7% on Jefferies launch at Buy\" data-tweet=\"$GTN - Gray Television +1.7% on Jefferies launch at Buy https://seekingalpha.com/news/3318300-gray-televisionplus-1_7-on-jefferies-launch-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3318300-gray-televisionplus-1_7-on-jefferies-launch-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318298\" data-ts=\"1513261523\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRBP\" target=\"_blank\">CRBP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318298-corbus-up-4-premarket-on-launch-of-late-stage-study-of-anabasum-in-systemic-sclerosis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Corbus up 4% premarket on launch of late-stage study of anabasum in systemic sclerosis</a></h4><ul><li>Corbus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CRBP' title='Corbus Pharmaceuticals Holdings, Inc.'>CRBP</a>) is up&nbsp;<font color='green'>4%</font>&nbsp;premarket on light volume in response to the <a href=\"https://seekingalpha.com/pr/17026929-corbus-pharmaceuticals-initiates-resolveminus-1-phase-3-study-systemic-sclerosis\" target=\"_blank\">initiation </a>of a Phase 3 clinical trial, RESOLVE-1, assessing lead candidate anabasum in patients with systemic sclerosis, an Orphan Drug- and Fast Track-designated indication.</li><li>The primary endpoint will be the change from baseline in skin fibrosis as measured by a scale called mRSS.</li><li>Dosing should wind up by late 2019 with an NDA to follow, assuming positive results, in mid-2020.</li><li>Anabasum is an oral synthetic endocannabinoid-mimetic that preferentially binds to the&nbsp;<a href=\"https://en.wikipedia.org/wiki/Cannabinoid_receptor_type_2\" target=\"_blank\">cannabinoid receptor type 2</a>&nbsp;(CB2) expressed on activated immune cells and&nbsp;<a href=\"https://en.wikipedia.org/wiki/Fibroblast\" target=\"_blank\">fibroblasts</a>. Activating CB2 triggers biochemical pathways that halt fibrosis and inflammation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318298\" data-linked=\"Corbus up 4% premarket on launch of late-stage study of anabasum in systemic sclerosis\" data-tweet=\"$CRBP - Corbus up 4% premarket on launch of late-stage study of anabasum in systemic sclerosis https://seekingalpha.com/news/3318298-corbus-up-4-premarket-on-launch-of-late-stage-study-of-anabasum-in-systemic-sclerosis?source=tweet\" data-url=\"https://seekingalpha.com/news/3318298-corbus-up-4-premarket-on-launch-of-late-stage-study-of-anabasum-in-systemic-sclerosis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318297\" data-ts=\"1513261315\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLDQ\" target=\"_blank\">SHLDQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318297-sears-starts-selling-diehard-products-on-amazon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sears starts selling DieHard products on Amazon</a></h4><ul> <li>Shares of Sears Holdings (SHLD) jump in early trading after some of the company's DieHard products <a href=\"https://seekingalpha.com/pr/17026981-diehard-celebrates-50th-anniversary-product-launch-amazon-com\" target=\"_blank\">jump</a> onto Amazon's website for consumers to snap up.</li> <li>Sometime next year, Sears will sell DieHard car tires and car batteries on Amazon as well.</li> <li>SHLD <font color='green'>+6.98%</font> premarket to $4.29.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3318297\" data-linked=\"Sears starts selling DieHard products on Amazon\" data-tweet=\"$SHLDQ - Sears starts selling DieHard products on Amazon https://seekingalpha.com/news/3318297-sears-starts-selling-diehard-products-on-amazon?source=tweet\" data-url=\"https://seekingalpha.com/news/3318297-sears-starts-selling-diehard-products-on-amazon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318294\" data-ts=\"1513261170\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOLD\" target=\"_blank\">FOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318294-amicus-submits-u-s-marketing-application-for-fabry-med-migalastat-shares-up-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amicus submits U.S. marketing application for Fabry med migalastat; shares up 2% premarket</a></h4><ul><li>Amicus Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FOLD' title='Amicus Therapeutics, Inc.'>FOLD</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;premarket, albeit on only 200 shares, in response to its <a href=\"https://seekingalpha.com/pr/17026928-amicus-therapeutics-submits-new-drug-application-u-s-fda-migalastat-treatment-fabry-disease\" target=\"_blank\">announcement </a>that it has filed a New Drug Application &#40;NDA&#41; with the FDA seeking approval for migalastat for the patients at least 16 years old with Fabry disease who have amenable mutations.</li><li>Fabry disease is an inherited lysosomal storage disorder caused by deficiency of an enzyme called alpha-galactosidase A (alpha-Gal A), which is the result of mutations in the GLA gene</li><li>Orphan Drug- and Fast Track-tagged migalastat, branded as Galafold, is a chaperone therapy that works by stabilizing the body's dysfunctional alpha-Gal A so it can clear the accumulation of disease substrate in patients with certain genetic mutations.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3277848-fda-confirms-amicus-therapeutics-may-submit-nda-migalastat-fabry-disease-shares-ahead-28\" target=\"_blank\">FDA confirms Amicus Therapeutics may submit NDA for Migalastat for Fabry disease; shares ahead 28% premarket</a> (July 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318294\" data-linked=\"Amicus submits U.S. marketing application for Fabry med migalastat; shares up 2% premarket\" data-tweet=\"$FOLD - Amicus submits U.S. marketing application for Fabry med migalastat; shares up 2% premarket https://seekingalpha.com/news/3318294-amicus-submits-u-s-marketing-application-for-fabry-med-migalastat-shares-up-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3318294-amicus-submits-u-s-marketing-application-for-fabry-med-migalastat-shares-up-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318293\" data-ts=\"1513261030\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318293-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/SMIT' title='Schmitt Industries, Inc.'>SMIT</a> <font color='green'>+69%</font> on <a href=\"https://seekingalpha.com/news/3318135-schmitt-industries-reports-q2-results\" target=\"_blank\">revenue growth</a>.</li><li><a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='green'>+20%</font> on <a href=\"https://seekingalpha.com/news/3318233-teva-cut-workforce-25-percent-suspends-dividend-shares-3-percent-premarket\" target=\"_blank\">dividend suspension</a>.</li><li><a href='https://seekingalpha.com/symbol/AEY' title='ADDvantage Technologies Group, Inc.'>AEY</a> <font color='green'>+18%</font> on <a href=\"https://seekingalpha.com/news/3318248-addvantage-technologies-reports-q4-results\" target=\"_blank\">Q4 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc'>MBOT</a> <font color='green'>+13%</font> on receiving patent allowance notice for their <a href=\"https://seekingalpha.com/pr/17026875-microbot-receives-notice-allowance-u-s-patent-covering-tipcat-technology-platform\" target=\"_blank\">TipCAT technology platform</a>.</li><li><a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a> <font color='green'>+13%</font> on news of <a href=\"https://seekingalpha.com/news/3318261-borrowing-bitcoin\" target=\"_blank\">borrowing against bitcoin</a>.</li><li><a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='green'>+10%</font> on launch of EksoGT <a href=\"https://seekingalpha.com/pr/17027026-ekso-bionics-partners-hasomed-launch-functional-electrical-stimulation-fes-eksogt-exoskeleton\" target=\"_blank\">through partnership</a> with HASOMED.</li><li><a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a> <font color='green'>+9%</font> on <a href=\"https://seekingalpha.com/pr/17027159-cellectar-files-ind-phase-1-trial-clr-131-pediatric-cancers\" target=\"_blank\">filing IND for Phase I trial</a> with Oncology division.</li><li><a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a> <font color='green'>+9%</font>.</li><li><a href='https://seekingalpha.com/symbol/AMPE' title='Ampio Pharmaceuticals, Inc.'>AMPE</a> <font color='green'>+7%</font> on <a href=\"https://seekingalpha.com/news/3318254-ampio-4-percent-premarket-positive-late-stage-results-ampion-knee-osteoarthritis\" target=\"_blank\">positive results</a> for Ampion in knee osteoarthritis.</li><li>PSDV <font color='green'>+6%</font> on <a href=\"https://seekingalpha.com/pr/17026864-hss-psivida-report-positive-phase-1-knee-osteoarthritis-pain-study-data\" target=\"_blank\">positive results</a> for Phase I of knee osteoarthritis pain study.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318293\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$SMIT $TEVA $AEY - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3318293-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3318293-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318289\" data-ts=\"1513260769\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318289-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/PIR' title='Pier 1 Imports Inc.'>PIR</a>&nbsp;<font color='red'>-27%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3318137-pier-1-imports-beats-0_11-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li>     <li><a href='https://seekingalpha.com/symbol/CRTO' title='Criteo S.A.'>CRTO</a>&nbsp;<font color='red'>-17%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3318281-criteo-minus-12_4-percent-expected-impact-apple-change\" target=\"_blank\">expected</a> impact from Apple change.</li>     <li><a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='red'>-13%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/TNTR-OLD' title='Tintri, Inc.'>TNTR-OLD</a>&nbsp;<font color='red'>-12%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3318131-tintri-eps-line-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li>     <li><a href='https://seekingalpha.com/symbol/GPP' title='Green Plains Partners'>GPP</a> <font color='red'>-11%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a>&nbsp;<font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3318224-proteostasis-prices-stock-offering-5-shares-1-percent-premarket\" target=\"_blank\">pricing</a> stock offering at $5.</li>     <li><a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a>&nbsp;<font color='red'>-10%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3318119-aethlon-medical-breaks-shares-38-percent\" target=\"_blank\">breaking out</a>.</li>     <li><a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a> <font color='red'>-7%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/FTR' title='Frontier Communications Corporation'>FTR</a>&nbsp;<font color='red'>-6%</font>&nbsp;on FCC <a href=\"https://seekingalpha.com/news/3318197-net-neutrality-coming-end\" target=\"_blank\">repealing</a> net neutrality rules.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318289\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$PIR $CRTO $SBGL - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3318289-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3318289-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318287\" data-ts=\"1513260574\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MITL\" target=\"_blank\">MITL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318287-mitel-networksplus-5_4-on-craig-hallum-initiation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mitel Networks +5.4% on Craig-Hallum initiation</a></h4><ul><li>        Craig-Hallum <a href=\"https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=1&amp;ved=0ahUKEwjsqIvw1YnYAhUL74MKHYW6BYkQFggnMAA&amp;url=https%3A%2F%2Fwww.streetinsider.com%2FAnalyst%2BComments%2FCraig-Hallum%2BStarts%2BMitel%2B%28MITL%29%2Bat%2BBuy%2F13600121.html&amp;usg=AOvVaw1S7ATdS8f6_d4rkuVInJwe\" target=\"_blank\">initiates</a> Mitel Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/MITL' title='Mitel Networks Corporation'>MITL</a>) at a Buy rating and $14 price target.</li><li>               Analyst George Sutton says the company &ldquo;has a $25 billion hunting license as its installed base of 70 million users hits technology refresh cycles.&rdquo;&nbsp;</li><li>               Mitel Networks shares are&nbsp;<font color='green'>up 5.4%</font>&nbsp;premarket. &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3318287\" data-linked=\"Mitel Networks +5.4% on Craig-Hallum initiation\" data-tweet=\"$MITL - Mitel Networks +5.4% on Craig-Hallum initiation https://seekingalpha.com/news/3318287-mitel-networksplus-5_4-on-craig-hallum-initiation?source=tweet\" data-url=\"https://seekingalpha.com/news/3318287-mitel-networksplus-5_4-on-craig-hallum-initiation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318286\" data-ts=\"1513260474\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROKU\" target=\"_blank\">ROKU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318286-rokuplus-4_7-fox-to-maintain-stake-after-disney-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roku +4.7%; Fox to maintain stake after Disney deal</a></h4><ul>   <li>Roku (NASDAQ:<a href='https://seekingalpha.com/symbol/ROKU' title='Roku Inc.'>ROKU</a>) is <font color='green'>up 4.7%</font> premarket following word that key shareholder Fox will <a href=\"https://seekingalpha.com/news/3318244-fox-deal-news-sports-growth-company-shares-reverse-lower\" target=\"_blank\">keep its equity investment</a> in the spin-off company despite selling other media assets to Walt Disney.</li>    <li>That retains a key foothold in streaming media despite Fox's selling its stake in Hulu to Disney.</li>    <li>Fox is also joined as a key investor in closely held Roku by Fidelity and Viacom.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318286\" data-linked=\"Roku +4.7%; Fox to maintain stake after Disney deal\" data-tweet=\"$ROKU - Roku +4.7%; Fox to maintain stake after Disney deal https://seekingalpha.com/news/3318286-rokuplus-4_7-fox-to-maintain-stake-after-disney-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3318286-rokuplus-4_7-fox-to-maintain-stake-after-disney-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318281\" data-ts=\"1513259746\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRTO\" target=\"_blank\">CRTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318281-criteominus-12_4-on-expected-impact-from-apple-change\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Criteo -12.4% on expected impact from Apple change</a></h4><ul><li>        Criteo (NASDAQ:<a href='https://seekingalpha.com/symbol/CRTO' title='Criteo S.A.'>CRTO</a>) <a href=\"https://seekingalpha.com/pr/17026999-criteo-provides-update-q4-2017-outlook-impact-business-apples-itp\" target=\"_blank\">updates</a> the expected impact of Apple&rsquo;s Intelligent Tracking Prevention (NYSEMKT:<a href='https://seekingalpha.com/symbol/ITP' title='IT Tech Packaging, Inc.'>ITP</a>).</li><li>                  Criteo says recent changes to iOS invalidates the company&rsquo;s projected 9% to 13% net negative impact on FY18 revenue ex-TAC. &nbsp;   </li><li>               The iOS 11.2 update blocks the ad ecosystem Criteo uses to reach Safari users. The company is working on an &ldquo;alternative sustainable solution for the long term&rdquo; but can&rsquo;t yet assess its effectiveness.&nbsp;</li><li>               If the new solution doesn&rsquo;t mitigate ITP impact, Criteo expects a 22% net negative impact on FY18 revenue. &nbsp;&nbsp;</li><li>Criteo shares are&nbsp;<font color='red'>down 12.4%</font>&nbsp;premarket.&nbsp; &nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3306548-criteo-q3-report-issues-weak-guidance-apple-itp-impact\" target=\"_blank\">Criteo down after Q3 report issues weak guidance, Apple ITP impact</a> (Nov. 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318281\" data-linked=\"Criteo -12.4% on expected impact from Apple change\" data-tweet=\"$CRTO - Criteo -12.4% on expected impact from Apple change https://seekingalpha.com/news/3318281-criteominus-12_4-on-expected-impact-from-apple-change?source=tweet\" data-url=\"https://seekingalpha.com/news/3318281-criteominus-12_4-on-expected-impact-from-apple-change\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318270\" data-ts=\"1513258633\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIOD\" target=\"_blank\">DIOD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318270-sidoti-upgrades-diodes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sidoti upgrades Diodes</a></h4><ul><li>        Sidoti <a href=\"https://markets.ft.com/data/equities/tearsheet/forecasts?s=DIOD:NSQ\" target=\"_blank\">upgrades</a> Diodes (NASDAQ:<a href='https://seekingalpha.com/symbol/DIOD' title='Diodes Incorporated'>DIOD</a>) from Neutral to Buy.</li><li>               Latest analyst recommendations: 1 Buy, 4 Hold.&nbsp;</li><li>               Median price target: $36.&nbsp;</li><li>               Diodes shares are&nbsp;<font color='green'>up 1.4%</font>&nbsp;premarket to $27.62.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3318270\" data-linked=\"Sidoti upgrades Diodes\" data-tweet=\"$DIOD - Sidoti upgrades Diodes https://seekingalpha.com/news/3318270-sidoti-upgrades-diodes?source=tweet\" data-url=\"https://seekingalpha.com/news/3318270-sidoti-upgrades-diodes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318263\" data-ts=\"1513258101\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCM\" target=\"_blank\">CMCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318263-cheetah-mobileplus-2_6-on-microsoft-collab\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cheetah Mobile +2.6% on Microsoft collab</a></h4><ul><li>           Cheetah Mobile (NYSE:<a href='https://seekingalpha.com/symbol/CMCM' title='Cheetah Mobile Inc.'>CMCM</a>) <a href=\"https://seekingalpha.com/pr/17026609-cheetah-mobile-collaborates-microsoft-ai-services\" target=\"_blank\">announces</a> a collaboration to incorporate Microsoft&rsquo;s AI technology and services into its products. &nbsp; </li><li>           The first phase integrates Microsoft&rsquo;s Cortana virtual assistant into Cheetah&rsquo;s CM Launcher mobile launcher app. </li><li> CM Launcher with Cortana is now available in open beta for users in the U.S., Britain, Canada, and Australia with the official release coming next month. &nbsp; </li><li>           Cheetah Mobile shares are&nbsp;<font color='green'>up 2.6%</font>&nbsp;premarket.&nbsp; </li><li>    Previously: <a href=\"https://seekingalpha.com/news/3313764-cheetah-mobile-plus-11_4-percent-q3-results-upside-guidance\" target=\"_blank\">Cheetah Mobile +11.4% after Q3 results, upside guidance</a> (Nov. 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318263\" data-linked=\"Cheetah Mobile +2.6% on Microsoft collab\" data-tweet=\"$CMCM - Cheetah Mobile +2.6% on Microsoft collab https://seekingalpha.com/news/3318263-cheetah-mobileplus-2_6-on-microsoft-collab?source=tweet\" data-url=\"https://seekingalpha.com/news/3318263-cheetah-mobileplus-2_6-on-microsoft-collab\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318257\" data-ts=\"1513257277\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318257-mkm-raises-micron-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MKM raises its Micron price target</a></h4><ul><li>        MKM Partners <a href=\"https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=1&amp;ved=0ahUKEwjqipaayInYAhXG64MKHXk3CH8QFggnMAA&amp;url=https%3A%2F%2Fwww.streetinsider.com%2FAnalyst%2BPT%2BChange%2FMicron%2BTechnology%2B%28MU%29%2BPT%2BRaised%2Bto%2B%2454%2Bat%2BMKM%2BPartners%2C%2BSays%2BMemory%2BTrends%2BAppear%2BTo%2BRemain%2BLargely%2BFavorable%2F13599841.html&amp;usg=AOvVaw3CiLuIHr4YoLALOma3YAog\" target=\"_blank\">raises</a> its Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) price target by $2 to $54 while maintaining a Buy rating. &nbsp;</li><li>        Latest analyst<a href=\"https://markets.ft.com/data/equities/tearsheet/forecasts?s=MU:NSQ\" target=\"_blank\"> recommendations</a>: 10 Buy, 18 Outperform, and 3 Hold.</li><li>               Median price target: $50.50.&nbsp;</li><li>               Micron shares are<font color='green'> up 1.1%</font>&nbsp;premarket.&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3318257\" data-linked=\"MKM raises its Micron price target\" data-tweet=\"$MU - MKM raises its Micron price target https://seekingalpha.com/news/3318257-mkm-raises-micron-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3318257-mkm-raises-micron-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>65&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318254\" data-ts=\"1513257155\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMPE\" target=\"_blank\">AMPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318254-ampio-up-4-premarket-on-positive-late-stage-results-for-ampion-in-knee-osteoarthritis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ampio up 4% premarket on positive late-stage results for Ampion in knee osteoarthritis</a></h4><ul><li>Ampio Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/AMPE' title='Ampio Pharmaceuticals, Inc.'>AMPE</a>) is up&nbsp;<font color='green'>4%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/17026903-ampio-pharmaceuticals-reports-positive-results-primary-secondary-endpoints-pivotal-phase-3\" target=\"_blank\">announcement </a>of positive results from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03182686?spons=ampio&amp;phase=2&amp;rank=2\" target=\"_blank\">Phase 3 clinical trial</a> assessing Ampion in patients with severe osteoarthritis of the knee.</li><li>The study met its primary endpoint with a 71% response rate which exceeded the physician-reported threshold of 30% (p&lt;0.001).</li><li>Responders experienced an average decrease in pain of 53%, an average improvement in function of 50% and an average improvement in quality-of-life score of 45%.</li><li>On the safety front, Ampion was well-tolerated with treatment-emergent adverse events on par with placebo.</li><li>Detailed results will be submitted for presentation at an upcoming scientific conference.</li><li><a href=\"http://ampiopharma.com/pipeline/ampion/\" target=\"_blank\">Ampion</a>, administered via injection into the knee joint, is a low molecular weight fraction of human serum albumin &#40;HSA&#41;. Its main ingredient is an immunomodulatory molecule derived from HSA called aspartyl-alanyl diketopiperazine (DA-DKP), believed to reduce inflammation by suppressing pro-inflammatory cytokine production in T cells.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318254\" data-linked=\"Ampio up 4% premarket on positive late-stage results for Ampion in knee osteoarthritis\" data-tweet=\"$AMPE - Ampio up 4% premarket on positive late-stage results for Ampion in knee osteoarthritis https://seekingalpha.com/news/3318254-ampio-up-4-premarket-on-positive-late-stage-results-for-ampion-in-knee-osteoarthritis?source=tweet\" data-url=\"https://seekingalpha.com/news/3318254-ampio-up-4-premarket-on-positive-late-stage-results-for-ampion-in-knee-osteoarthritis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318249\" data-ts=\"1513256570\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LULU\" target=\"_blank\">LULU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318249-lululemon-tracks-higher-after-deutsche-bank-raves-on\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lululemon tracks higher after Deutsche Bank raves on</a></h4><ul> <li>Deutsche Bank upgrades Lululemon (NASDAQ:<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a>) to a <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Deutsche+Bank+Upgrades+Lululemon+Athletica+Inc.+%28LULU%29+to+Buy%3B+Sees+a+Q4+Beat+and+Smoothing+of+Bumps+in+the+Road/13599637.html\" target=\"_blank\">Buy rating</a> after having it set at Hold.</li> <li>The investment firm calls LULU an \"ace of innovation\" in a glowing note to clients in which it also raised the price target on the apparel stock to a Street-high $89.</li> <li>Analyst Paul Trussell sees fewer bumps in the roader for Lululemon and clearer visibility on profit growth in the men's, international and digital businesses.</li> <li>LULU <font color='green'>+2.44%</font> premarket to $76.50.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318249\" data-linked=\"Lululemon tracks higher after Deutsche Bank raves on\" data-tweet=\"$LULU - Lululemon tracks higher after Deutsche Bank raves on https://seekingalpha.com/news/3318249-lululemon-tracks-higher-after-deutsche-bank-raves-on?source=tweet\" data-url=\"https://seekingalpha.com/news/3318249-lululemon-tracks-higher-after-deutsche-bank-raves-on\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318235\" data-ts=\"1513254556\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOX\" target=\"_blank\">FOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318235-mouse-eats-fox-shares-up-implications-for-hulu-film-franchises-updated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mouse eats Fox: Shares up; implications for Hulu, film franchises (updated)</a></h4><ul>     <li>Fox shares are on the move premarket -- <a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='green'>up 1.6%</font> to $32.85, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='green'>up 2%</font> to $33.40 -- after confirmation of the <a href=\"https://seekingalpha.com/news/3318228-mega-media-disney-confirms-fox-deal\" target=\"_blank\">biggest deal in Walt Disney's history</a> gets it the bulk of Fox's content businesses.</li>     <li>Disney is <font color='green'>up 1.5%</font> premarket.</li>     <li>The deal comes at a higher-than-reported enterprise value of $66.1B after Disney agrees to take on about $13.7B in Fox's net debt.</li>     <li>As reported, Fox's spinco will hold Fox broadcast, Fox News and its national sports networks in operations that will have an EBITDA of about $2.8B. That smaller enterprise could in time be combined with News Corp. (<a href='https://seekingalpha.com/symbol/NWS' title='News Corporation'>NWS</a>, <a href='https://seekingalpha.com/symbol/NWSA' title='News Corporation'>NWSA</a>)</li>     <li>Along with film and television studio assets (and combining two of Hollywood's Big Six studios), Disney takes over cable entertainment including FX and National Geographic, and Fox's 39% stake in Sky (<a href='https://seekingalpha.com/symbol/SKYAY' title='Sky Plc ADR'>OTCPK:SKYAY</a>) and stake in Star India along with nearly two dozen regional sports nets -- the last of which might raise government concerns on combination with ESPN.</li>     <li>The combination will bring even more Marvel rights into Disney's empire, including the <i>X-Men, Fantastic Four</i> and <i>Deadpool</i> franchises/assets, along with <i>Avatar</i> -- the highest-grossing worldwide picture of all time and the subject of several upcoming sequels/spin-offs (as well as part of key theme park assets).</li>     <li>Disney becomes the majority partner in Hulu, taking a 60% share with the rest held by remaining partners Comcast (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) and Time Warner (NYSE:<a href='https://seekingalpha.com/symbol/TWX' title='Time Warner Inc.'>TWX</a>).</li>     <li><strong>Updated 8 a.m.</strong>:&nbsp;Disney shares have turned <font color='red'>1.3% lower</font>, and Fox has turned down as well: <a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='red'>-3%</font>; <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='red'>-2.6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318235\" data-linked=\"Mouse eats Fox: Shares up; implications for Hulu, film franchises (updated)\" data-tweet=\"$FOX $FOX $FOXA - Mouse eats Fox: Shares up; implications for Hulu, film franchises (updated) https://seekingalpha.com/news/3318235-mouse-eats-fox-shares-up-implications-for-hulu-film-franchises-updated?source=tweet\" data-url=\"https://seekingalpha.com/news/3318235-mouse-eats-fox-shares-up-implications-for-hulu-film-franchises-updated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318233\" data-ts=\"1513254251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318233-teva-to-cut-workforce-25-suspends-dividend-shares-up-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva to cut workforce 25%, suspends dividend; shares up 3% premarket</a></h4><ul><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) <a href=\"https://seekingalpha.com/pr/17026891-teva-announces-restructuring-plan-additional-measures-improve-business-financial-performance\" target=\"_blank\">announces </a>its restructuring plan. Key points:</li><li>Workforce to be reduced 25% (14K positions globally).</li><li>Dividend suspended on ordinary shares and ADSs. Dividends on mandatory convertible preferred shares will be evaluated on a quarterly basis.</li><li>No annual bonuses will be paid this year.</li><li>Organizational structure to be simplified via reducing layers of management, streamlining processes and divesting/closing certain R&amp;D facilities.</li><li>Total cost base to be reduced $3B (from a base of $16.1B this year) by the end of 2019. More than half should be achieved by the end of next year.</li><li>Restructuring charge of $700M to be recorded in 2018.</li><li>2018 guidance will be provided in February with the release of 2017 results. Color on longer-term strategic direction will come later in 2018.</li><li>Shares are up&nbsp;<font color='green'>3%</font>&nbsp;premarket on modest volume.</li><li><strong>Update</strong>: In the conference call, management stated that it had no plans to issue additional equity.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318233\" data-linked=\"Teva to cut workforce 25%, suspends dividend; shares up 3% premarket\" data-tweet=\"$TEVA - Teva to cut workforce 25%, suspends dividend; shares up 3% premarket https://seekingalpha.com/news/3318233-teva-to-cut-workforce-25-suspends-dividend-shares-up-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3318233-teva-to-cut-workforce-25-suspends-dividend-shares-up-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>118&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318224\" data-ts=\"1513253080\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTI\" target=\"_blank\">PTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318224-proteostasis-prices-stock-offering-5-shares-down-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Proteostasis prices stock offering at $5; shares down 1% premarket</a></h4><ul><li>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a>) <a href=\"https://seekingalpha.com/pr/17026677-proteostasis-therapeutics-prices-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of 8M shares of common stock at $5 per share. Underwriters over-allotment is an additional 1.2M shares. Closing date is December 18.</li><li>Net proceeds will fund clinical trials, working capital and general corporate purposes.</li><li>Yesterday's close was $5.47.</li><li>Shares are down&nbsp;<font color='red'>1%</font>&nbsp;premarket on modest volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318224\" data-linked=\"Proteostasis prices stock offering at $5; shares down 1% premarket\" data-tweet=\"$PTI - Proteostasis prices stock offering at $5; shares down 1% premarket https://seekingalpha.com/news/3318224-proteostasis-prices-stock-offering-5-shares-down-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3318224-proteostasis-prices-stock-offering-5-shares-down-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318218\" data-ts=\"1513252764\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318218-valeant-downgraded-to-underweight-jpmorgan-shares-down-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valeant downgraded to Underweight by JPMorgan; shares down 5% premarket</a></h4><ul><li>Valeant Pharmaceuticals (VRX) is down&nbsp;<font color='red'>5%</font>&nbsp;premarket on modest volume on the heels of a <a href=\"https://www.streetinsider.com/Analyst+Comments/JPMorgan+Downgrades+Valeant+Pharmaceuticals+%28VRX%29+to+Underweight+Citing+Stretched+Valuation%2C+Leverage+Remains+Challenging/13599563.html\" target=\"_blank\">downgrade </a>to Underweight with a $12 (46% downside risk) price target by JPMorgan.</li><li>Analyst Chris Schott cites valuation and \"too high\" 2018 estimates.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318218\" data-linked=\"Valeant downgraded to Underweight by JPMorgan; shares down 5% premarket\" data-tweet=\"$BHC - Valeant downgraded to Underweight by JPMorgan; shares down 5% premarket https://seekingalpha.com/news/3318218-valeant-downgraded-to-underweight-jpmorgan-shares-down-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3318218-valeant-downgraded-to-underweight-jpmorgan-shares-down-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>246&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":55,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}